Proteo, Inc. / Proteo Biotech AG: FDA Grants Proteo Orphan Drug Designation to Elafin for the Treatment of Pulmonary Arterial Hypertension

Published: Jan 10, 2013

IRVINE, Calif. & KIEL, Germany--(BUSINESS WIRE)--Proteo, Inc. (OTCQB: PTEO) and its wholly-owned subsidiary Proteo Biotech AG announced today: The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Elafin for the treatment of pulmonary arterial hypertension.

Back to news